Neural Regeneration Research ›› 2022, Vol. 17 ›› Issue (3): 567-568.doi: 10.4103/1673-5374.320985

Previous Articles     Next Articles

Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies

Emanuele D’Amico*, #, Aurora Zanghì#, Carlo Avolio   

  1. Department “G.F. Ingrassia”; MS Center, University of Catania, Catania, Italy (D’Amico E, Zanghì A) 
    Department of Medical and Surgical Sciences, University of Foggia; Multiple Sclerosis Center, Department of Neurosciences, Policlinico Riuniti Hospital, Foggia, Italy (Avolio C)
  • Online:2022-03-15 Published:2021-10-15
  • Contact: Emanuele D’Amico, MD, emanuele.damico@unict.it.

PDF

83

Abstract: The approval of oral disease modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has changed considerably the therapeutic scenario and they often represent the first therapeutic choice for patients with RRMS, since their safety and efficacy profile has been extensively validated (D’Amico et al., 2015).